Physician profile
Tracy L Genovese
NPI 1518585462
$1,695.66
in general payments reported to CMS, 2019-2025
12 companies · $87.42 in 2025
The $87.42 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $589 · 2023: $1,019 · 2025: $87.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,106.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $433.62 | 2022-2023 | |
| Abbvie INC. | $363.41 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $189.68 | 2022-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $142.66 | 2022-2023 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $124.04 | 2022-2023 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $122.73 | 2023 | Auvelity |
| Corium, LLC | $110.59 | 2022-2023 | Azstarys |
| Janssen Pharmaceuticals, INC | $102.37 | 2022-2023 | Spravato |
| Tris Pharma INC | $56.73 | 2022-2023 | Dyanavel Xr |
| Almatica Pharma LLC | $18.52 | 2023 | Sertraline Hcl, Loreev Xr |
| Vanda Pharmaceuticals INC. | $16.79 | 2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $14.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Genovese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.